182 related articles for article (PubMed ID: 36198529)
21. Novel treatments for relapsed/refractory acute myeloid leukemia with
Tallis E; Borthakur G
Expert Rev Hematol; 2019 Aug; 12(8):621-640. PubMed ID: 31232619
[No Abstract] [Full Text] [Related]
22. The most novel of the novel agents for acute myeloid leukemia.
Perl AE
Curr Opin Hematol; 2018 Mar; 25(2):81-89. PubMed ID: 29278535
[TBL] [Abstract][Full Text] [Related]
23. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract][Full Text] [Related]
24. FLT3 Inhibition in Acute Myeloid Leukemia.
Smith CC
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S5-S6. PubMed ID: 32862867
[TBL] [Abstract][Full Text] [Related]
25. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
26. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
27. Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?
Pratz KW; Luger SM
Curr Opin Hematol; 2014 Mar; 21(2):72-8. PubMed ID: 24468836
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.
Best-Aguilera C; Rodrigo Gómez-Vázquez O; Elizabeth Guzmán-Hernández A; Monserrat Rojas-Sotelo R
Curr Oncol Rep; 2017 Mar; 19(3):21. PubMed ID: 28283965
[TBL] [Abstract][Full Text] [Related]
29. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Brinton LT; Zhang P; Williams K; Canfield D; Orwick S; Sher S; Wasmuth R; Beaver L; Cempre C; Skinner J; Cannon M; Govande M; Harrington B; Lehman A; Byrd JC; Lapalombella R; Blachly JS
J Hematol Oncol; 2020 Oct; 13(1):139. PubMed ID: 33076970
[TBL] [Abstract][Full Text] [Related]
30. Targeting FLT3 to treat leukemia.
Konig H; Levis M
Expert Opin Ther Targets; 2015 Jan; 19(1):37-54. PubMed ID: 25231999
[TBL] [Abstract][Full Text] [Related]
31. Emergence of crenolanib for FLT3-mutant AML.
Fathi AT
Blood; 2013 Nov; 122(22):3547-8. PubMed ID: 24263951
[TBL] [Abstract][Full Text] [Related]
32. FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.
Grunwald MR; Levis MJ
Semin Hematol; 2015 Jul; 52(3):193-9. PubMed ID: 26111466
[TBL] [Abstract][Full Text] [Related]
33. The rocky road to personalized medicine in acute myeloid leukaemia.
Brinda B; Khan I; Parkin B; Konig H
J Cell Mol Med; 2018 Mar; 22(3):1411-1427. PubMed ID: 29327808
[TBL] [Abstract][Full Text] [Related]
34. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
35. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
[TBL] [Abstract][Full Text] [Related]
36. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
Pemmaraju N; Kantarjian H; Ravandi F; Cortes J
Cancer; 2011 Aug; 117(15):3293-304. PubMed ID: 21319142
[TBL] [Abstract][Full Text] [Related]
37. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
Knapper S
Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
[TBL] [Abstract][Full Text] [Related]
38. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
[No Abstract] [Full Text] [Related]
39. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
Larrosa-Garcia M; Baer MR
Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
[TBL] [Abstract][Full Text] [Related]
40. Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy.
Hu S; Liu J; Chen S; Gao J; Zhou Y; Liu T; Dong X
Biol Pharm Bull; 2021; 44(12):1872-1877. PubMed ID: 34853270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]